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BAR domains can prevent membrane fission through
their ability to shield necks of budding vesicles from
fission-inducing factors. However, the physiological
role of this inhibitory function and its regulation is
unknown. Here we identify a checkpoint involving
the BAR-domain-containing protein Arfaptin-1 that
controls biogenesis of secretory granules at the
trans-Golgi network (TGN). We demonstrate that
protein kinase D (PKD) phosphorylates Arfaptin-1 at
serine 132, which disrupts the ability of Arfaptin-1
to inhibit the activity of ADP ribosylation factor,
an important component of the vesicle scission
machinery. The physiological significance of this
regulatory mechanism is evidenced by loss of
glucose-stimulated insulin secretion due to granule
scission defects in pancreatic b cells expressing
nonphosphorylatable Arfaptin-1. Accordingly, deple-
tion of Arfaptin-1 leads to the generation of small
nonfunctional secretory granules. Hence, PKD-medi-
ated Arfaptin-1 phosphorylation is necessary to
ensure biogenesis of functional transport carriers
at the TGN in regulated secretion.
INTRODUCTION
Sorting and packaging of cargo, proper coating of vesicles and
their subsequent detachment from the trans-Golgi network
(TGN) require complex and dynamic mechanisms (Kirchhausen,
2000). These are particularly important in specialized secretory
cells in which big amounts of cargo are transported in vesicles
from the TGN to the plasma membrane for subsequent release.
Regulated secretion of insulin from pancreatic b cells constitutes
one important example as its lack in mammals is incompatible
with life and its dysfunction leads to diabetes (Muoio and
Newgard, 2008). While most attention has been drawn to distal
steps of insulin exocytosis, i.e., vesicle fusion with the plasma756 Developmental Cell 23, 756–768, October 16, 2012 ª2012 Elsevmembrane (Eliasson et al., 2008), mechanisms underlying
correct formation of the secretory granule are still poorly eluci-
dated. Recently, we described the requirement of protein kinase
D 1 (PKD1) in pancreatic b cells to control TGN function and
insulin secretion (Sumara et al., 2009). Several subsequent
studies corroborated the importance of PKD1 in insulin release
(Kong et al., 2010; Saini et al., 2010; Subathra et al., 2011).
PKD1, together with PKD2 and PKD3 belong to the protein
kinase D (PKD) family of serine/threonine protein kinases of the
calcium/calmodulin-dependent kinase group (Rozengurt et al.,
2005). Among other important cellular functions (Fu and Rubin,
2011; Rykx et al., 2003), PKD was suggested to control fission
of surface-destined cargo-containing vesicles from the TGN
(Liljedahl et al., 2001). PKD has been shown to regulate lipid-
modifying effectors at the TGN (Fugmann et al., 2007; Hausser
et al., 2005; Ngo and Ridgway, 2009), which may impact on
membrane dynamics and thus vesicle formation as well as
secretion (Malhotra andCampelo, 2011). By binding to diacylgly-
cerol (DAG), PKD is recruited to TGN membranes (Baron and
Malhotra, 2002) where it can associate with ADP-ribosylation
factor 1 (ARF1) (Pusapati et al., 2010). ARFs are members of
the Ras superfamily of small GTPases and are involved both in
vesicle budding (Kirchhausen, 2000; Spang, 2008) and vesicle
fission (Beck et al., 2011; Pucadyil and Schmid, 2009; Valente
et al., 2012) at the TGN. Class I ARFs (ARF1 and ARF3) and
Class II ARFs (ARF4 and ARF5) localize to the Golgi compart-
ment, whereas class III ARFs (ARF6) localize to the plasma
membrane (Gillingham and Munro, 2007). In addition to these
three classes, there are over 20 ARF-like (ARL) proteins in the
ARF protein family. Although the GDP-GTP switch of ARF family
members is well studied (Donaldson and Jackson, 2011), the
mechanisms that direct ARFs to their site of action and govern
their interaction with their multiple downstream effectors are
poorly understood.
One group of potential ARF regulators is the Arfaptin family
consisting of Arfaptin-1, Arfaptin-2, protein kinaseC-bindingpro-
tein 1 (PICK1), and islet cell antigen 69 kDa (ICA69) (Habermann,
2004). Two of itsmembers, Arfaptin-1 and 2, have been shown to
interact with ARF1, ARF3, ARF5, ARF6, and ARL1 (Kanoh et al.,
1997; Man et al., 2011; Shin and Exton, 2001). The defining
feature of Arfaptins is the crescent Bin/amphiphysin/Rvs (BAR)ier Inc.
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membrane dynamics as their crescent shape allows them to
impose or sense curvature on lipid bilayers (McMahon and
Gallop, 2005). Recent in vitro studies have shown opposing roles
of amphipathic helices and BAR domains in membrane fission
(Boucrot et al., 2012; Mim et al., 2012). Crescent BAR domains
stabilize tubular membrane structures and limit the access of
proteins with amphipathic helices, which are sufficient to induce
fission. However, the physiological relevance of the inhibition of
fission by BAR domains and mechanisms of its regulation have
not been elucidated thus far.
Here we show that secretory granule biogenesis at the Golgi
requires the BAR domain protein Arfaptin-1 and its regulation
by PKD to prevent premature fission and generation of non-
functional transport carriers. In addition, we demonstrate that
Arfaptin-1 is pivotal for maintaining insulin secretion from
pancreatic b cells, highlighting the physiological relevance of
this mechanism.
RESULTS
PKD Phosphorylates Arfaptin-1 In Vitro and In Vivo
To address a potential functional link between PKD and ARFs,
we screened ARFs and known direct interactors of ARFs for
PKD consensus phosphorylation motifs (LXRXXpS) and crossre-
ferenced the hits with a recent phosphoproteomic study (Huttlin
et al., 2010). Arfaptin-1 displayed a single PKD consensus site,
which was phosphorylated in several analyzed tissues (Huttlin
et al., 2010). This potential PKD phosphorylation site is present
in both the long and short Arfaptin-1 isoform, which differ by
32 amino acids in the N-terminal region. The candidate serine
is located at position 132 in the long and at position 100 in the
short isoform. This site is highly conserved in vertebrates but is
absent in the Arfaptin-1 paralog Arfaptin-2 (Figure 1A).
To prove that Arfaptin-1 is a direct target of PKD, we per-
formed an in vitro kinase assay. Full-length recombinant human
Arfaptin-1 was strongly phosphorylated by recombinant active
PKD1 (Figure 1B). Addition of the PKD inhibitor Go¨6976 (Haxhi-
nasto and Bishop, 2003) abrogated phosphorylation of wild-type
Arfaptin-1. Replacement of serine 132 by alanine (Arfaptin-1
S132A) led to complete loss of the phosphorylation signal
(Figure 1B). In order to address Arfaptin-1 phosphorylation in
cells, we raised a monoclonal antibody against phosphorylated
Arfaptin-1, that recognized only phosphorylated wild-type
Arfaptin-1 and did not reveal a signal for Arfaptin-1 S132A (Fig-
ure 1C). Cells expressing both Flag-tagged wild-type Arfaptin-1
and green fluorescent protein (GFP)-tagged wild-type PKD1
showed strong phosphorylation of exogenous Arfaptin-1 (Fig-
ure 1D). Cells coexpressing wild-type Arfaptin-1 and GFP alone
showed weak but detectable basal phosphorylation, most
likely due to basal activity of endogenous PKD1. Coexpression
of wild-type Arfaptin-1 with a GFP-tagged K618N kinase-dead
mutant of PKD1 (PKD1 KD-GFP) decreased the signal below
basal phosphorylation levels. This is in line with the fact that
PKD1 KD acts in a dominant-negative fashion (Liljedahl et al.,
2001). Phosphorylation was abolished when Arfaptin-1 S132A
was coexpressed either with GFP, wild-type PKD1 or PKD1
KD-GFP. Phosphorylation of endogenous Arfaptin-1 was not
detectable in this experiment. Abundance of endogenous orDevelopmexogenous Arfaptin-1 was not affected upon expression of
wild-type and PKD1 KD-GFP. To substantiate dependence of
Arfaptin-1 phosphorylation on PKD1 activity, we generated
stable knockdowns of PKD1 and corresponding nonsilencing
control cells and expressed Flag-tagged wild-type Arfaptin-1.
In nonsilencing cells, kinase activity-dependent autophosphory-
lation of PKD1 was strongly induced by phorbol myristate
acetate (PMA), a known activator of PKD1 (Valverde et al.,
1994) (Figure 1E). Activation and abundance of PKD1 was
strongly reduced for both independent PKD1 knockdowns.
Phosphorylation of exogenous Arfaptin-1 was only detected
in stimulated cells and was markedly reduced in cells with a
knockdown of PKD1 (Figure 1E). In conclusion, these data
demonstrate that PKD1 phosphorylates Arfaptin-1 at serine
132 in vitro and in vivo.
Phosphorylation at Serine 132 Delocalizes
Arfaptin-1 from the Golgi
To study the functional role of Arfaptin-1 phosphorylation, we
examined the effects of PKD1 activity on subcellular localiza-
tion of Arfaptin-1 and Arfaptin-2. Arfaptin-1 and 2 colocalized
with the Golgi protein Giantin in nontransfected cells (Figures
S1A and S1B available online), which is in line with recently re-
ported Golgi localization of these two proteins (Man et al.,
2011). Expression of GFP alone did not affect localization of
Arfaptin-1 and 2. In contrast, in cells expressing PKD1-GFP,
most Arfaptin-1 delocalized from the Golgi (Figure 2A), while
Arfaptin-2 localization was not affected. Expression of a GFP-
tagged constitutively active form of PKD1, in which two activa-
tory serines in the activation loop (serine 744 and 748) have
been replaced by glutamic acids (PKD1 2S2E-GFP), led to
the same effects (Figure 2A). However, expression of PKD1
KD-GFP did not lead to delocalization of Arfaptin-1 or 2 from
the Golgi (Figure 2A) corroborating the requirement of PKD1
kinase activity for controlling Arfaptin-1 localization.
We next investigated whether PKD1-dependent phosphoryla-
tion of Arfaptin-1 is required for its change in localization. We
coexpressedwild-type PKD1 or PKD1KD-GFPwith Flag-tagged
wild-type or Arfaptin-1 S132A. Expression of wild-type PKD1
led to delocalization of wild-type Arfaptin-1 from the Golgi,
while expression of PKD1 KD-GFP had no effect (Figure S1C).
In strong contrast, Arfaptin-1 S132A remained at the Golgi
even when PKD1 was coexpressed, indicating that serine 132
phosphorylation is required for the change in localization of
Arfaptin-1 (Figure S1C).
We next addressed whether serine 132 phosphorylation is
sufficient to induce Arfaptin-1 delocalization from the Golgi.
We expressed GFP-tagged wild-type Arfaptin-1, Arfaptin-1
S132A, and a phosphomimetic mutant of Arfaptin-1 in which
serine 132 is replaced with an aspartate (Arfaptin-1 S132D).
Wild-type Arfaptin-1 was mainly localized at the Golgi. However,
a minor cytoplasmic distribution was detected (Figure 2B),
while Arfaptin-1 S132A was more strictly confined to the Golgi
apparatus with significantly less detectable cytoplasmic locali-
zation. In strong contrast, Arfaptin-1 S132Dwas diffusely distrib-
uted throughout the cytoplasm with minimal retention on Golgi
structures (Figure 2B). These results suggest that Arfaptin-1
phosphorylation at serine 132 is required and sufficient to
induce its change in localization.ental Cell 23, 756–768, October 16, 2012 ª2012 Elsevier Inc. 757
Figure 1. PKD Phosphorylates Arfaptin-1 at Serine 132
(A) Protein sequence alignment of human Arfaptin-2 and Arfaptin-1 as well as of Arfaptin-1 in indicated species. The phosphorylation site is highlighted in red
and its position within the full-length protein is indicated below. The region in blue is only present in the longer isoform 1.
(B) In vitro kinase assay using recombinant GST-taggedwild-type humanArfaptin-1 (hArfaptin-1) and serine to alaninemutant Arfaptin-1 (hArfaptin-1 S132A) after
addition of recombinant PKD1 without or with the PKD inhibitor Go¨6976.
(C) Recombinant wild-type Arfaptin-1 and Arfaptin-1 S132A incubated with or without recombinant PKD1 were blotted using monoclonal antibodies against
phosphorylated serine 132 of Arfaptin-1 (P-Arfaptin-1 Ser132). Anti-GST was used as loading control.
(D) Whole-cell lysates of HEK293T cells expressing indicated PKD1 and Arfaptin-1 constructs were blotted for PKD1, phospho-Arfaptin-1 Ser132 and Arfaptin-1.
Anti-tubulin was used as loading control. The filled arrow indicates exogenous PKD1, the open arrow endogenous PKD1. l.e., low exposure; h.e., high
exposure. Both endogenous Arfaptin-1 isoforms can be detected in cells expressing Flag control in the higher exposure panel.
(E) Whole-cell lysates of HEK293T cells infected with lentiviruses containing two independent shRNA against PKD1 (shPKD1#1 and shPKD1#2) or nonsilencing
shRNA and transiently transfected with Arfaptin-1 Flag were blotted using antibodies against autoactivatory phosphorylation of serine 916 of PKD1 (P-PKD1
Ser916), PKD1, P-Arfaptin-1 Ser132 and Flag. Anti-GAPDH was used as loading control. Cells were stimulated with 10 nM phorbol myristate acetate (PMA)
for 15 min where indicated.
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Arfaptin-1-Mediated Inhibition of ARF Activity
and Allows Vesicle Formation at the Golgi In Vitro
Given the proximity of serine 132 to the BAR domain, we next
addressed whether phosphorylation influences its functions.
Since Arfaptins need to dimerize to establish the crescent
shaped BAR domains (Tarricone et al., 2001) we tested if
dimerization is affected by phosphorylation. Incubation of re-
combinant glutathione S-transferase (GST)-tagged wild-type
Arfaptin-1, Arfaptin-1 S132A, or Arfaptin-1 S132D with lysates
from cells that overexpressed Flag-tagged wild-type Arfaptin-1758 Developmental Cell 23, 756–768, October 16, 2012 ª2012 Elsevand subsequent GST pull-downs showed that Arfaptin-1 phos-
phorylation at serine 132 does not influence the protein’s ability
to form homodimers (Figure S2A). Using deletion mutants, Wil-
liger et al. identified two regions in Arfaptin-1 that are necessary
for ARF3 binding (Williger et al., 1999). Since one of them
contains serine 132, we examined changes in ARF binding.
GST pull-downs were performed with recombinant wild-type
Arfaptin-1, Arfaptin-1 S132A, or Arfaptin-1 S132D in presence or
absence of guanosine 50-O-[gamma-thio]triphosphate (GTPgS)
with lysates from cells expressing ARF1-HA, ARL1-Myc,
or ARF3-HA. ARFs and ARL1 coprecipitated with wild-typeier Inc.
Figure 2. Phosphorylation of Arfaptin-1 at
Serine 132 Delocalizes It from the Golgi
(A) Confocal images of HeLa cells expressing GFP,
PKD1-GFP, PKD1 2S2E-GFP, or PKD1 KD-GFP.
Endogenous Arfaptin-1 and Arfaptin-2 were
stained by immunofluorescence and nuclei with
DAPI. Arrows indicate reduction of Golgi-localized
Arfaptin-1.
(B) Confocal images of HeLa cells transiently
expressing GFP-tagged wild-type Arfaptin-1
(Arfaptin-1 GFP), GFP-tagged serine to alanine
mutant (Arfaptin-1 S132A-GFP) or GFP-tagged
serine to aspartate mutant Arfaptin-1 (Arfaptin-1
S132D-GFP). Giantin staining was used to high-
light the Golgi.
See also Figure S1.
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Arfaptin-1 Controls Secretory Granule BiogenesisArfaptin-1 and Arfaptin-1 S132A only in the presence of
GTPgS (Figures 3A and 3B; Figure S2B), confirming previously
reported specificity of Arfaptin-1 for the active (GTP-bound)
form of these small GTPases (Kanoh et al., 1997). Strikingly,
however, Arfaptin-1 S132D did not interact with ARFs or ARL1
(Figures 3A and 3B; Figure S2B). Likewise, Flag-tagged wild-Developmental Cell 23, 756–768type Arfaptin-1 or Arfaptin-1 S132A
coimmunoprecipitated HA-tagged con-
stitutive active ARF1 (ARF1 Q71L) and
endogenous ARL1, while Arfaptin-1
S132D did not (Figures 3C and 3D).
Importantly, binding to Arfaptin-1 S132A
was markedly higher than binding to
wild-type Arfaptin-1 as phosphorylation
of the latter was likely to occur in cells
due to endogenous PKD activity. To
corroborate these findings, we also per-
formed GST pull-downs with unphos-
phorylated and PKD1-phosphorylated
wild-type Arfaptin-1 with lysates from
cells expressing ARF1-HA, confirming
data obtained with mutant Arfaptin-1 (Fig-
ure S2C). We thus conclude that PKD1-
mediated phosphorylation of Arfaptin-1
prevents its binding to ARF and ARF-like
family members. As binding to ARF family
members is required for Golgi localization
of Arfaptin-1 (Kanoh et al., 1997; Man
et al., 2011), this finding is in line with the
change in Arfaptin-1 localization that is
observed upon its phosphorylation by
PKD1.
We subsequently addressed whether
Arfaptin-1 shields activated ARFs or
ARF-like proteins from interacting with
their downstream effectors. Recently, it
has been reported that ARL1 binds and
recruits BIG1 and BIG2, guanine nucleo-
tide exchange factors (GEFs) of ARF1
and 3, to the TGN (Christis and Munro,
2012). Interestingly, recruitment of BIG
was inhibited by ectopic expression ofArfaptin-1 due to steric hindrance of the interaction of ARL1
with BIG. We thus asked whether phosphorylation at serine
132 abolishes this effect. In GFP-expressing cells, BIG2 local-
ized to the Golgi. In cells expressing GFP-tagged wild-type
Arfaptin-1 or Arfaptin-1 S132A, however, localization of BIG2
at the Golgi was dramatically reduced (Figure 3E). In contrast,, October 16, 2012 ª2012 Elsevier Inc. 759
Figure 3. Phosphorylation of Arfaptin-1 at Serine 132 Disrupts Its Interaction with ARF Family Members and Releases Their Inhibition
(A) Western blot after GST pull-down from lysates of HEK293T lysates expressing hemagglutinin (HA)-tagged ADP ribosylation factor 1 (ARF1-HA) incubated with
recombinant wild-type Arfaptin-1 (Arfaptin-1GST), serine to alaninemutant Arfaptin-1 (Arfaptin-1GSTS132A), or serine to aspartatemutant Arfaptin-1 (Arfaptin-1
GST S132D). Antibodies against GST and HA were used to detect proteins with respective tags. GTPgS was added where indicated to lock the small GTPases
in their active conformation. GST pull-down and input are shown as indicated.
(B) Western blot after GST pull-down from lysates of HEK293T lysates expressing Myc-tagged ARF-like 1 (ARL1-Myc) incubated with recombinant wild-type
Arfaptin-1 GST, Arfaptin-1 GST S132A, or Arfaptin-1 GST S132D. Antibodies against GST and Myc were used to detect proteins with respective tags. GTPgS
was added where indicated to lock the small GTPases in their active conformation. GST pull-down and input are shown as indicated.
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zation. Our data thus confirm that binding of active ARL1 by
Arfaptin-1 inhibits its interaction with BIG2 and demonstrate
that this mechanism is dependent on the phosphorylation status
of Arfaptin-1. PKD1 may thus act to derepress Arfaptin-1-
imposed inhibition of ARFs, ARF-like proteins and their effectors.
This mechanism thus adds another level of ARF regulation
beyond classical GTPase cycling.
ARFs contain amphipathic helices that can make shallow
insertions into membranes. ARFs were shown to promote
membrane fission in their GTP-bound form. In an in vitro recon-
stitution assay, Beck et al. have shown that ARF1 dimerization is
necessary for vesicle fission (Beck et al., 2011). Using the same
assay, we investigated whether the phosphorylation status of
Arfaptin-1 influences the ability of ARF1 to generate vesicles
from purified Golgi. Addition of Arfaptin-1 S132D did not affect
vesicle formation as seen both by western blotting (Figure 3F)
and electron microscopy (Figure 3G) of the purified vesicle frac-
tion. However, addition of Arfaptin-1 S132A almost completely
abolished vesicle generation in vitro (Figures 3F and 3G). These
data thus suggest that Arfaptin-1 blocks ARF activity and Golgi
vesicle formation in its unphosphorylated state, but allows
transport carrier generation to occur upon its phosphorylation
and release from ARF proteins.
Phosphorylation of Arfaptin-1 by PKD
and Delocalization of Arfaptin-1 Occur
in Insulin-Secreting Cells
Recently, we discovered that PKD1 controls TGN dynamics in
b cells to regulate insulin secretion and glucose homeostasis
in mice (Sumara et al., 2009). We thus asked whether PKD1-
mediated phosphorylation of Arfaptin-1 occurs in insulin-secret-
ing cells in response to a physiologic stimulus. To this end, we
performed immunoprecipitations of endogenous phosphory-
lated Arfaptin-1 in a rat insulinoma-derived b cell line (INS-1) after
stimulation with the insulin secretagogue carbachol, an acetyl-
choline analog and known activator of PKD1 (Sumara et al.,
2009). In unstimulated cells, Arfaptin-1 phosphorylation was
below the detection limit (Figure 4A). Carbachol stimulation,
however, inducedphosphorylationofArfaptin-1,whichwasabol-
ishedwhenPKD1was inhibitedwithGo¨6976 (Figure 4A).Wenext
analyzed whether carbachol stimulation affected endogenous
Arfaptin-1 localization in INS-1 cells. In unstimulated INS-1 cells,
Arfaptin-1 was localized at the Golgi and to a lesser extent in the
cytoplasm (Figure 4B). Stimulation by carbachol led to a sig-
nificant decrease of Arfaptin-1 signal at the Golgi. Incubation(C) Anti-Flag immunoprecipitation from lysates of HEK293T cells coexpressing
Arfaptin-1, Arfaptin-1 S132A, or Arfaptin-1 S132D. Antibodies against HA and Fla
and input are shown as indicated.
(D) Anti-Flag immunoprecipitation from lysates of HEK293T cells expressing Flag-
against ARL1 and Anti-Flag were used to detect endogenous ARL1 and tagged
(E) Confocal images of cells expressing GFP, GFP-tagged wild-type Arfaptin1 (
serine to aspartatemutant Arfaptin1 (Arfip1 S132D-GFP). Cells were stained for BI
of Golgi-localized BIG2.
(F and G) Vesicles were reconstituted from isolated Golgi membranes using A
GST-tagged recombinant Arfaptin-1 mutant protein as indicated. The vesicle frac
(F) Western blot of the purified vesicle fraction of the ARF1 vesicle reconstitutio
amounts of d-COP and ARF1 after vesicle purification. (G) Negative staining elect
See also Figure S2.
Developmwith the PKD inhibitor Go¨6976 decreased carbachol-induced
Arfaptin-1 delocalization (Figures 4B and 4C). Thus, physiologic
stimulation of PKD activity induces phosphorylation and de-
localization of endogenous Arfaptin-1 in b cells.
Nonphosphorylatable Arfaptin-1 Interferes with
Glucose-Stimulated Insulin Secretion by Blocking
Insulin Granule Fission at the Golgi
ARF activity has been shown to be crucial in regulated secretion
(Be´gle´ et al., 2009; Sadakata et al., 2010). As shown above,
PKD1-dependent phosphorylation of Arfaptin-1 regulates its
interaction with ARF and ARF-like proteins and Golgi vesicle
formation in vitro. We thus asked whether PKD-mediated
Arfaptin-1 phosphorylation regulates insulin granule formation
at the TGN, thereby having impact on insulin secretion.
To answer this question, we investigated short- and long-term
effects of pharmacological inhibition of PKD on glucose-
stimulated insulin secretion (GSIS). Since Go¨6976 was toxic for
INS-1 cells for incubations longer than 8 hr, we used CID
755673, a more specific, cell-active PKD inhibitor of the newest
generation (Sharlow et al., 2008). CID 755673 efficiently reduced
carbachol-stimulated PKD1 activation in INS-1 cells already
after 30 min of inhibitor treatment (Figure 5A). In spite of efficient
PKD inhibition, no significant reduction in GSIS was measurable
1 hr after inhibitor treatment (Figure 5B). Thus, PKD activity is
very unlikely to affect fusion of readily releasable insulin granules
that have been generated prior inhibition. After 8 hr of inhibitor
treatment, however, stimulated insulin release was significantly
reduced. After 24 hr of inhibitor treatment, GSIS was almost
completely abolished (Figure 5B). The time frame of the secre-
tion block by PKD inhibition suggests failures in generation and
replenishment of functional secretory granules and corroborates
a defect at the Golgi level.
To examine whether nonphosphorylatable Arfaptin-1 can
mimic the effect of PKD inhibition, we expressed GFP-tagged
wild-type Arfaptin-1, Arfaptin-1 S132A, and Arfaptin-1 S132D
in INS-1 cells (Figure S3A). Expression of wild-type protein
caused a significant decrease in GSIS. Strikingly, Arfaptin-1
S132A almost entirely blocked stimulated insulin release, while
Arfaptin-1 S132D had no significant effect on GSIS (Figure 5C).
From these results, we conclude that ectopic expression of
wild-type Arfaptin-1 shifted the balance between Arfaptin-1-
mediated ARF inhibition and PKD1-dependent derepression of
the latter, resulting in a moderate loss of GSIS. The S132A
mutant, however, was no longer released from binding to ARFs
and ARF-like proteins by PKD1 causing a significantly strongerHA-tagged constitutive active ARF1 (ARF1 Q71L) and Flag-tagged wild-type
g were used to detect proteins with respective tags. Flag immunoprecipitation
tagged wild-type Arfaptin-1, Arfaptin-1 S132A, or Arfaptin-1 S132D. Antibodies
proteins. Flag immunoprecipitation and input are shown as indicated.
Arfaptin1-GFP), serine to alanine mutant Arfaptin1 (Arfaptin1 S132A-GFP), or
G2, Giantin andDAPIwas used to stain the nuclei. Arrows indicate the reduction
RF1 in the presence of GTPgS, purified coatomer and recombinant GST or
tion was separated from Golgi membranes via sucrose density centrifugation.
n assay. The amount of generated vesicles was measured by quantifying the
ron microscopy of vesicles generated in the ARF1 vesicle reconstitution assay.
ental Cell 23, 756–768, October 16, 2012 ª2012 Elsevier Inc. 761
Figure 4. PKD Phosphorylates Arfaptin-1 in Insulin-Secreting Cells upon a Physiologic PKD Stimulus
(A) Immunoprecipitation of phosphorylated Arfaptin-1 (P-Arfaptin-1) from lysates of INS-1 cells stimulated for 15 min with 100 mM carbachol where indicated in
presence or absence of the PKD inhibitor Go¨6976. Antibodies against Arfaptin-1, autoactivatory phosphorylation of serine 916 of PKD1 (P-PKD1 Ser916), PKD1,
andGAPDH (loading control) were used to detect respective proteins. Open arrows point to Arfaptin-1-specific bands. The filled arrow indicates PKD1. * indicates
unspecific bands.
(B) Immunofluorescence of INS-1 cells stimulated for 15 min with 100 mM carbachol in presence or absence of the PKD inhibitor Go¨6976. Cells were stained for
Arfaptin-1 and Giantin. DAPI was used to stain nuclei.
(C) Quantification of relative Arfaptin-1 to Giantin signal intensity on Golgi (n = 10). ns, nonsignificant. *p < 0.05; **p < 0.01; ***p < 0.001 (Student’s t test). Error bars
indicate mean ± SEM.
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ARF-like proteins and is mostly cytoplasmic. Hence, binding of
endogenous Arfaptin-1 to ARFs or ARF-like proteins and its regu-
lation by PKD1 was unimpeded resulting in normal secretion.
Subsequently, we addressed whether Arfaptin-1 overexpres-
sion also interferes with constitutive secretion. To this end, we
cotransfected a thermosensitive VSV-G mutant (Presley et al.,
1997) with Arfaptin-1 Flag, Arfaptin-1 S132A Flag, Arfaptin-1
S132D Flag, or Flag control into INS-1 cells. No differences in
VSV-G trafficking were detected (Figure S3B), indicating that
expression of Arfaptin-1 or its mutants does not affect constitu-
tive secretion. These results were confirmed using secreted
embryonic alkaline phosphatase (SEAP) (Figure S3C). Hence,
expression of Arfaptin-1 or Arfaptin-1 S132A interferes with
regulated secretion, but does not alter constitutive secretion in
b cells.
Given strong inhibition of ARF1-mediated vesicle formation by
Arfaptin-1 S132A in vitro and the striking effects on GSIS in vivo,
we subsequently explored if the nonphosphorylatable mutant
interferes with granule biogenesis. We thus proceeded to
investigate insulin granule morphology and distribution using
electron microscopy. While there was no significant change in
total cellular granule numbers (see Table S1), the distribution762 Developmental Cell 23, 756–768, October 16, 2012 ª2012 Elsevof granules throughout the cell was severely altered in cells
expressing Arfaptin-1 S132A as compared to controls. The
number of granules close to the plasma membrane was sig-
nificantly reduced, while the number of granules in the Golgi
compartment or the surrounding cytoplasm was more than
doubled (Figure 5D; Figures S3D and S3E). Most strikingly,
Arfaptin-1 S132A-expressing cells revealed many neck-shaped
membrane structures connecting insulin granules with each
other or with the Golgi apparatus (Figure 5E). Such structures
were almost not detectable in control cells (Figure 5F). Both
the increased number of necks and prevalence of unsuccessfully
separated granule structures point to a severe defect in
membrane scission. Interestingly, the phenotype was associ-
ated with a slightly reduced total insulin content (Figure S3A).
Conclusively, nonphosphorylatable Arfaptin-1 limits fission
of insulin transport carriers and replenishment of functional
secretory granules.
Arfaptin-1-Imposed Inhibition of Membrane Fission
at the Golgi Serves as a Checkpoint for Proper
Insulin Granule Formation
Lack of Arfaptin-1 phosphorylation interferes with ARF function,
insulin granule biogenesis and insulin secretion. However, anier Inc.
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if negative regulation of ARF activity by Arfaptin-1 is lost in cells?
To answer this question, we established a stable knockdown of
Arfaptin-1 in INS-1 cells (Figure S4A). Strikingly, depletion of
Arfaptin-1 almost completely abolished insulin secretion in
response to glucose (Figure 6A). Furthermore, there was no
additional effect of PKD inhibition with CID 755673 on GSIS in
Arfaptin-1-depleted INS-1 cells underscoring the importance of
Arfaptin-1 as a target of PKD (Figure S4B). No differences in
VSV-G trafficking were detectable in Arfaptin-1 depleted as
compared to control cells (Figure S4C), indicating that loss of
Arfaptin-1 does not affect constitutive secretion. These results
were confirmed using SEAP (Figure S4D) corroborating a
specific function of Arfaptin-1 in regulated but not constitutive
secretion.
Since our experiments implicated Arfaptin-1 in granule scis-
sion, we analyzed granule morphology and distribution using
quantitative transmission electron microscopy (TEM). Compar-
ison of the total number of insulin granules in Arfaptin-1 knock-
down and control cells did not show any significant differences
(Table S1). However, the size of secretory granules in INS-1 cells
depleted of Arfaptin-1 was markedly reduced (Figures 6B and
6C). Moreover, in control cells the majority of granules were
found in proximity of the plasma membrane. These vesicles
constitute the reserve pool of secretory granules (Rorsman
et al., 2000). In INS-1 cells depleted of Arfaptin-1, however,
the number of granules close to the plasma membrane was
markedly reduced (Figure 6D). Likewise, the amount of granules
primed for insulin release and docked with the plasma
membrane—the readily releasable pool—was strongly dimin-
ished (Figure 6E). Instead, secretory granules of Arfaptin-1
knockdown cells were found distributed throughout the cyto-
plasm indicating their inability to reach the plasma membrane
(Figure 6F).
Since defective insulin granule biogenesis is likely to affect
packaging of insulin into transport carriers, we analyzed both
proinsulin and insulin levels in control and Arfaptin-1 knockdown
cells. Both proinsulin and insulin levels were strongly reduced in
cells lacking Arfaptin-1 (Figure 6G). To exclude that the latter was
a result of decreased proinsulin production, we performed pulse-
chase experiments with radioactively labeled S35-methionine.
After 30 min of label incorporation both control and Arfaptin-1
knockdown cells showed comparable proinsulin levels indi-
cating that preproinsulin transcription, translation and conver-
sion to proinsulin occurs normally in Arfaptin-1 depleted cells
(Figure 6H). After 3 hr of chase the proinsulin signal in control
cells was no longer detectable, since proinsulin had been
successfully converted into insulin. In Arfaptin-1 knockdown
cells, the proinsulin band was gone as well; however, only
a very weak band for mature insulin was detectable (Figure 6H).
Thus, the pulse-chase experiment did not show a delay or defect
in insulin conversion in Arfaptin-1-deficient cells. Instead, the
data indicate that a significant portion of labeled hormone had
not been stored in functional secretory granules and was most
likely rapidly degraded. These results provide strong evidence
that Arfaptin-1 is necessary for correct formation of secretory
granules and thus stimulated insulin secretion.
Altogether, our data demonstrate that Arfaptin-1 inhibits
fission of insulin granules prior its phosphorylation by PKD toDevelopmprevent formation of nonfunctional transport carriers in insulin-
secreting b cells.
DISCUSSION
Recently, the mechanisms how BAR-domain-containing
proteins regulate membrane fission have been uncovered (Bou-
crot et al., 2012; Mim et al., 2012). Our study demonstrates how
the activity of one of them, Arfaptin-1, is regulated to ensure
proper secretory granule formation at the Golgi of pancreatic
b cells.
The BAR domain of Arfaptin-1 is known to sense highly posi-
tive membrane curvatures (Habermann, 2004; Peter et al.,
2004). The highest membrane curvature at the Golgi is found
at the neck of a growing vesicle. Arfaptin-1 has thus a tropism
for the vesicle neck (Habermann, 2004), and has the potential
to stabilize it by forming a scaffold that prevents membrane
fission (Boucrot et al., 2012; Mim et al., 2012). Shedding of
such a scaffold would not only physically destabilize the vesicle
neck, but would subsequently allow access for the scission
complex. Thus, as long as Arfaptin-1 is bound to activated
ARF at the vesicle neck, ARF is shielded from interaction with
downstream effectors and fission is prevented (Figure 7A).
Once PKD phosphorylates Arfaptin-1 at serine 132, it is
released from ARF and fission inhibition is relieved (Figure 7B).
The actual machinery that accomplishes fission of secretory
granules is unknown so far. One interesting possibility is that
scission is mediated directly by ARF dimers, which have the
ability to fission membranes through their N-terminal amphi-
pathic helices (Beck et al., 2011). A similar mechanism has
been reported for another ARF family member, Sar1, and the
fission of Coat Protein (COP) II-coated vesicles (Bielli et al.,
2005). Alternatively, ARF may recruit a fission machinery (Fig-
ure 7C), as it has been shown that PKD and ARF are compo-
nents of a protein complex involved in carrier scission at the
TGN (Valente et al., 2012).
We show that PKD phosphorylates Arfaptin-1 at serine 132,
a modification that disrupts its binding to small GTPases of the
ARF family. Although the region including serine 132 has been
reported to be important for ARF binding (Williger et al., 1999),
it is not clear at this point how this phosphorylation event inter-
feres with ARF binding. So far two structures of Arfaptin in
complex with small GTPases have been resolved (Nakamura
et al., 2012; Tarricone et al., 2001). Crystallization experiments
in both studies were performed with N-terminally truncated
Arfaptin that does not contain serine 132. Nevertheless, the
structure of dimerized Arfaptin bound to two ARL1 molecules
published by Nakamura et al. (2012) demonstrated that binding
to ARF and binding to positively curved membranes (Haber-
mann, 2004; Peter et al., 2004) are not mutually exclusive as
they involve different interaction surfaces of the protein. It is likely
that both interactions work cooperatively to recruit Arfaptin-1 to
the neck of forming secretory granules.
Interestingly, our data show that Arfaptin-1 is necessary for
regulated but not constitutive secretion. Our results thus indi-
cate that control of membrane fission might be distinct for both
secretory pathways. The generation of transport carriers in
both secretory pathways requires ARFs. However, secretory
granules and constitutively secreted vesicles strongly differ inental Cell 23, 756–768, October 16, 2012 ª2012 Elsevier Inc. 763
Figure 5. PKD-Mediated Arfaptin-1 Phosphorylation Is Specifically Required for Insulin Granule Scission and Thereby Glucose-Stimulated
Insulin Secretion
(A) INS-1 cells were preincubated for 15 min with CID 755673 or DMSO control and subsequently stimulated for 15 min with 20 mM carbachol in the presence of
DMSO or CID 755673. Whole-cell lysates were blotted for P-PKD1 Ser916, PKD1, and GAPDH as loading control.
(B) Insulin secretion at basal (2.8 mM) and stimulatory (22 mM) glucose concentrations from INS-1 cells treated with DMSO or 30 mM PKD inhibitor CID 755673
for the indicated time period (n = 6).
(C) Insulin secretion from INS-1 cells stably expressing GFP, GFP-tagged wild-type Arfaptin-1, serine to alanine mutant Arfaptin-1 (Arfaptin-1 S132A-GFP) or
serine to aspartate mutant Arfaptin-1 (Arfaptin-1 S132D-GFP) under basal (2.8 mM) and stimulatory (22 mM) glucose concentrations (GFP n = 6, Arfaptin-1 GFP
n = 6, Arfaptin-1 S132A-GFP n = 6, Arfaptin-1 S132D-GFP n = 9).
(D) Representative transmission electron microscopy images of the Golgi area in GFP-expressing control and GFP-tagged Arfaptin-1 S132A-overexpressing
INS-1 cells. Arrows indicate secretory granules.
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Figure 6. Arfaptin-1 Is Necessary for Proper Insulin Granule Formation
(A) Insulin secretion from INS-1 cells infected with control nonsilencing (ns) or Arfaptin-1 knockdown (shArfaptin-1) constructs under basal (2.8 mM) and stim-
ulatory (22 mM) glucose concentrations (n = 6).
(B) Representative transmission electron microscopy images of nonsilencing (ns) control and Arfaptin-1 knockdown (shArfaptin-1) INS-1 cells. Arrows indicate
secretory granules. Dashed lines show the plasma membrane.
(C) Mean granule size of secretory granules in nonsilencing control or Arfaptin-1 knockdown INS-1 cells (n = 200).
(D) Quantification of the number of secretory granules in vicinity of the plasma membrane (n = 30).
(E) Quantification of the number of secretory granules docked to the plasma membrane (n = 30).
(F) Quantification of the number of secretory granules in the cytoplasm (n = 30).
(G) Total cell lysates of ns and shArfaptin-1 INS-1 cells separated on a Tricine gel. Antibodies against Proinsulin, Insulin and GAPDH (loading control) were used to
detect the respective proteins.
(H) Autoradiography of immunoprecipitated insulin after 30 min of S35 methionine incubation (pulse) and 3 hr of chase with nonradioactive medium (chase) in
control and Arfaptin-1 knockdown INS-1 cells. Autoradiography of total cell lysates before immunoprecipitation is shown as input.
In (A) and (C)–(F), *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test). Error bars indicate mean ± SEM. See also Figure S4.
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be due to its BAR domain that has a tropism for vesicle necks of
a specific size.(E) Magnifications of abnormal insulin granules in Arfaptin-1 S132A-overexpress
(F) Box plot of relative occurrence of unseparated granule structures in GFP contr
maximum values. Significance was calculated using Yates’ Chi-square test (n =
In (B) and (C), ns, nonsignificant; *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t t
DevelopmWe demonstrate that the release of Arfaptin-1 by PKD
phosphorylation is necessary for the formation of functional
granules in insulin-secreting cells. Both overexpression ofing cells. The dashed line indicates the granule membrane.
ol and Arfaptin-1 S132A-overexpressing cells. Whiskers indicate minimum and
30).
est). Error bars indicate mean ± SEM. See also Figure S3.
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Figure 7. Model of the Secretory Granule Scission Checkpoint
(A) Arfaptin-1 binds ARF-GTP at the neck of a growing secretory granule
precursor and forms a protective scaffold. As long as Arfaptin-1 is bound to an
ARF family member, the latter is shielded from interacting with downstream
effectors and cannot dimerize.
(B) Once the granule precursor has been completely loaded, its increased size
induces strong curvature at the vesicle neck, priming it for local diacylglycerol
(DAG, indicated as red lipids) accumulation. DAG is a strong activator of PKD
and recruits the kinase by binding to the C1a and C1b domain. Active PKD
phosphorylates Arfaptin-1 at serine 132 and releases it from ARFs.
(C) ARFs that are no longer shielded by Arfaptin-1 induce fission via their
amphipathic helices after dimerization or nucleate together with PKD a scis-
sion complex. Finally, the scission machinery detaches the secretory granule
precursor from the TGN.
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inhibition of PKD activity interfere with insulin secretion in
response to glucose. Remarkably, pharmacological inhibition
of PKD does not block secretion immediately. This observation
suggests that granules that have been formed before PKD
inhibition can still be secreted. However, secretory defects
upon PKD inhibition become apparent at later time points,
where replenishment of newly formed functional granules
is essential to maintain secretion. This observation is also
corroborated by the presence of nonfunctional granules and
obvious fission defects in Arfaptin-1 S132A-overexpressing
cells. Interestingly, the fission defect in these cells resulted in
incompletely separated granules of normal size, which may
imply the existence of an upper granule size limit. However, it
is unknown so far whether an unidentified vesicle coat or
different size sensing mechanisms limit the granule size.
Loss-of-function experiments also strongly support a role of
Arfaptin-1 in generation of functional insulin granules as secre-
tory granules in Arfaptin-1 knockdown cells are small and
nonfunctional. Additionally, our pulse-chase experiments show
that a significant portion of newly synthesized proinsulin in cells
depleted of Arfaptin-1 is rapidly degraded instead of being
properly stored in functional secretory granules. This conclusion
is further supported by decreased total insulin and proinsulin
levels in Arfaptin-1 knockdown cells. Interestingly, granule
numbers in Arfaptin-1 knockdown and control cells were
comparable. Degradation of improperly formed granules may
thus counteract increased granule generation due to premature
fission finally resulting in comparable numbers of granules,
which are small, nonfunctional and contain less insulin. This
phenotype can be explained by the absence of a checkpoint
that halts vesicle fission until all necessary components
have been sorted into the forming granule. We suggest that
Arfaptin-1 and PKD are at the core of this checkpoint and ensure
that only properly formed secretory granules can detach from
the Golgi.
How PKD senses that a granule precursor is ready for release
from the TGN is still unclear. However, diacylglycerol (DAG), a
phospholipid known to be a strong activator of PKCs and PKD,
is enriched in membranes with high negative curvature due to
its small hydrophilic head and bulky hydrophobic tail (Szule
et al., 2002). Therefore, increasing curvature and accumulation
of DAG in the growing vesicle’s neck could account for local
PKD activation once the granule reaches a certain size.
A small perturbation in the process of granule formation can
blunt a b cell’s secretory capacity, as only a limited amount of
granules can be primed for release at a certain time (20 granules
per b cell; Eliasson et al., 2008). Thus, if this readily releasable
pool of vesicles is clogged up by a subpopulation of defective
granules, even correctly formed ones could no longer release
their cargo. Therefore, generation of defective transport carriers
could account for the commonly observed first- and second-
phase insulin secretion defects in patients suffering from type II
diabetes (Del Prato et al., 2002).
Altogether, our work uncovers a quality control mechanism of
transport carrier formation at the TGN that ensures continuous
replenishment of functional secretory granules. This mechanism
is pivotal in insulin-secreting cells and may thus be key in main-
taining glucose homeostasis and energy metabolism.ier Inc.
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Detailed experimental procedures are available in Supplemental Experimental
Procedures.
Glucose-Stimulated Insulin Secretion
GSIS was performed as previously described (Sumara et al., 2009). In brief,
INS-1 cells were starved for 30 min in Krebs-Ringer Bicarbonate Buffer
(KRB) (136 mM NaCl, 4.7 mM KCl, 1.2 mM MgS04, 1 mM CaCl2, 1.2 mM
KH2PO4, 5 mM NaHCO3, 10 mM HEPES [pH 7.4]) supplemented with 0.5%
BSA, and 2.8 mM glucose. Subsequently, INS-1 cells were incubated for
1 hr in the same buffer. The cellular supernatant was taken off as unstimulated
sample, and replaced by KRB supplemented with 0.5% BSA and 22 mM
glucose. After 1 hr the supernatant was taken off as stimulated sample and
the remaining cells were lysed in IP Buffer. The insulin secretion in the
supernatants was measured using an Ultra Sensitive Mouse Insulin ELISA
Kit (Christal Chem Inc.). Data were normalized to nonstimulated control
cells. To measure insulin secretion in INS-1 cells expressing exogenous
Arfaptin-1, cells were lentivirally transfected with GFP fusion constructs
72 hr before the secretion experiments.
ARF1 Vesicle Reconstitution Assay
One hundred twenty-five micrograms of salt-washed Golgi membranes
(Beck et al., 2009) was mixed with 5 mg myristoylated ARF1, 40 mg coatomer,
45 mg Arfaptin-1 mutants or 15 mg free GST, and 1 mM GTP in assay buffer
(25 mM HEPES-KOH [pH 7], 2.5 mM Mg-Acetate, 100 mM DTT) in a total
volume of 250 ml. After incubation for 10 min at 37C, the salt concentration
was raised to 250 mM KCl and the sample was centrifuged at 12,000 3 g
for 10 min. The supernatant containing COPI vesicles was loaded on top of
two sucrose cushions (5 ml of 50% and 50 ml of 37% sucrose) and centrifuged
for 50 min at 100,000 3 g in a SW60Ti rotor. COPI-coated vesicles were
concentrated at the interphase between 50% and 37% sucrose. Fifty percent
of the isolated vesicle fraction was analyzed by SDS-PAGE and western
blotting. For negative staining electron microscopy a carbon coated grid
was put on top of a 5 ml droplet of purified COPI vesicles. After 10 min of
adsorption at room temperature proteins were fixed by putting the grid onto
a 20 ml droplet of 1% glutaraldehyde in 1 3 assay buffer (25 mM HEPES-
KOH [pH 7], 2.5 mM MgAcetate), washed three times with 20 ml assay buffer
each and incubated for 5 min in 0.05% of tannic acid. All these steps were
performed at room temperature. Afterward, the sample was washed four
times with 20 ml water. Then staining was performed with 0.4% uranyl acetate
in 1.8% methylcellulose for 10 min on ice.
Pulse-Chase Insulin Biosynthesis Assay
Proinsulin biosynthesis and conversion of proinsulin to insulin were analyzed
by (pro)insulin immunoprecipitation of [35S]methionine-radiolabeled INS-1
lysates as described (Wicksteed et al., 2001). Briefly, INS-1 cells were incu-
bated in KRB with 25 mM glucose for 1 hr, the last 30 min of incubation was
carried out in the presence of 250 mCi/ml 35S-methionine (pulse). After pulse,
cells were washed and then chased for 0 or 3 hr in KRB buffer with 1.4 mM
glucose. At each chase time point, cells were collected, washed, lysed in IP
Buffer (50 mM Tris [pH 7.5], 50 mM NaCl, 0.5% Triton X-100, 0.5% NP40
substitute, 5 mM EGTA, 5 mM EDTA, 20 mM NaF, 25 mM beta-glycerophos-
phate, 1 mM PMSF, 0.1 mM NaVO3, 13 complete protease inhibitor [Roche])
and subsequently immunoprecipitated for (pro)insulin with anti-insulin anti-
body (I8510, Sigma). Immunoprecipitated 35S-labeled (pro)insulin was then
subjected to SDS-PAGE and visualized by phosphoimager.
VSV-G Constitutive Secretion Assay
The protocol for the VSV-G secretion assay was adapted from Valente et al.
(2012). In short, control or Arfaptin-1 knockdown INS-1 cells were trans-
fected with pEGFP-VSVG using the Amaxa Cell Line Nucleofector Kit T
(Lonza). Five hours after transfection cells were shifted to 40C for 30 hr.
Subsequently 100 mg/ml cycloheximide was added and the temperature
was shifted to 20C for 30 min. At this point the T0 sample was taken.
Cells were shifted to 32C for 2 hr and the T120 sample was taken and
samples were stained without permeabilization with anti-luminal VSVG
antibody and DAPI.DevelopmSEAP Constitutive Secretion Assay
Control or Arfaptin-1 knockdown INS-1 cells were transfected with
pBluescript-CMV-SEAP using the Amaxa Cell Line Nucleofector Kit T (Lonza).
SEAP enzymatic activity was measured in lysates and supernatants using
Quanti-Blue (Invivogene) according to the manufacturer’s instructions.
Statistical Analysis
Pairwise significance was calculated using two-tailed unpaired Student’s
t test in Microsoft Excel (Microsoft). Data were considered statistically sig-
nificant once p < 0.05. *p < 0.05; **p < 0.01; ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.devcel.2012.07.019.
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